FDA Approves Durvalumab as First Perioperative Immunotherapy for Gastric and GEJ Cancers

FDA Approves Keytruda–Padcev Combination as First Perioperative Treatment for Bladder Cancer

Sevabertinib Wins FDA Approval with Strong Responses in HER2-Mutated NSC Lung Cancer

FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma

FDA Approves Ziftomenib as a New Targeted Option for NPM1+ Acute Myeloid Leukemia

Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad

Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Kidney Cancer

Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer

ctDNA Blood Test Guides Chemotherapy Decisions for Tailored Colon Cancer Treatment

DeLLphi-303: Tarlatamab Plus Chemo Achieves 71% Response in ES Small-Cell Lung Cancer

ESMO’s Road Map for Safe and Effective Use of AI-LLMs in Cancer Care: 23 Rules from 20 Experts

Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer

Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer

Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer

Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival in Endometrial Carcinoma

AI Analysis of Thymic Health Predicts Immunotherapy Success, Cutting Death Risk by 44%

Disarming Prostate Cancer: Dual Enzyme Blockade Weakens Tumors and Boosts Drug Response

Molecular Trojan Horse: Peptide Nanotubes Offer a Path to Defeat Drug-Resistant Tumors

Reprogramming Cancer Cell Death: A New Immune-Based Strategy for Blood Cancers

AstraZeneca makes deal with Trump Admin to Cut Drug Prices 80% and Invest $50B in US

LED-Activated SnOx Nanoflake Therapy Destroy Tumor Cells with Precision

In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach

FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma

Datroway Improves Survival in First-Line Treatment of Metastatic Triple- Breast Cancer

FDA Approves Tecentriq–Zepzelca Combo as FL Maintenance Therapy for ES-SC Lung Cancer

The VAPOR 2 Trial and the Potential of Water Vapor Ablation in Prostate Cancer Treatment

DESTINY-Breast05: Enhertu Outperforms T-DM1 in High-Risk HER2+ Early Breast Cancer

Dr. Eleni Lagkadinou Discusses How AbbVie Is Advancing Targeted Innovation for HT Cancers

FDA Approves Imlunestrant for ESR1-Mutated Metastatic Breast Cancer

Giredestrant Plus Everolimus Improves PF Survival in ER+ Advanced Breast Cancer